Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV2-hAADC in Young Onset Parkinson's Disease
NCT07267065Phase 1Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of ezaladcigene resoparvovec in Parkinson's disease (PD) (2 arms). Primary endpoints: Adverse Events at 3 years, Magnetic Resonance Imaging findings at 6 months and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ezaladcigene resoparvovec
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07267065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07267065.